Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine-Reference-Cited by-同舟云学术

Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine

Published:2021-02-05 Issue:4 Volume:218 Page:
ISSN:0022-1007
Container-title:Journal of Experimental Medicine
language:en
Short-container-title:

Author:

Bastard Paul¹²³^ORCID,Michailidis Eleftherios⁴^ORCID,Hoffmann Hans-Heinrich⁴^ORCID,Chbihi Marwa¹²^ORCID,Le Voyer Tom¹²^ORCID,Rosain Jérémie¹²^ORCID,Philippot Quentin¹²^ORCID,Seeleuthner Yoann¹^ORCID,Gervais Adrian¹²^ORCID,Materna Marie¹²^ORCID,de Oliveira Patricia Mouta Nunes⁵^ORCID,Maia Maria de Lourdes S.⁵^ORCID,Dinis Ano Bom Ana Paula⁶^ORCID,Azamor Tamiris⁶^ORCID,Araújo da Conceição Deborah⁵^ORCID,Goudouris Ekaterini⁷^ORCID,Homma Akira⁵^ORCID,Slesak Günther⁸^ORCID,Schäfer Johannes⁸^ORCID,Pulendran Bali⁹¹⁰^ORCID,Miller Joseph D.⁹¹¹^ORCID,Huits Ralph¹²^ORCID,Yang Rui³^ORCID,Rosen Lindsey B.¹³^ORCID,Bizien Lucy¹²^ORCID,Lorenzo Lazaro¹²^ORCID,Chrabieh Maya¹²^ORCID,Erazo Lucia V.¹^ORCID,Rozenberg Flore¹⁴^ORCID,Jeljeli Mohamed Maxime¹⁵^ORCID,Béziat Vivien¹²³^ORCID,Holland Steven M.¹³^ORCID,Cobat Aurélie¹³^ORCID,Notarangelo Luigi D.¹³^ORCID,Su Helen C.¹³^ORCID,Ahmed Rafi⁹^ORCID,Puel Anne¹²³^ORCID,Zhang Shen-Ying¹²³^ORCID,Abel Laurent¹²³^ORCID,Seligman Stephen J.³¹⁶^ORCID,Zhang Qian³^ORCID,MacDonald Margaret R.⁴^ORCID,Jouanguy Emmanuelle¹²³^ORCID,Rice Charles M.⁴^ORCID,Casanova Jean-Laurent¹²³¹⁷^ORCID

Affiliation:

1. Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale U1163, Necker Hospital for Sick Children, Paris, France

2. University of Paris, Imagine Institute, Paris, France

3. St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY

4. Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY

5. Bio-Manguinhos, Fiocruz, Ministry of Health, Rio de Janeiro, Brazil

6. Laboratory of Immunological Techniques, Bio-Manguinhos, Fiocruz, Ministry of Health, Rio de Janeiro, Brazil

7. Federal University of Rio de Janeiro, Rio de Janeiro, Brazil

8. Tropical Medicine Department, Tropenklinik Paul-Lechler-Krankenhaus, Tübingen, Germany

9. Emory Vaccine Center and the Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA

10. Institute for Immunity, Transplantation and Infection, Department of Pathology, Department of Microbiology and Immunology, Stanford University, Stanford, CA

11. Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases, Division of Scientific Resources, Atlanta, GA

12. Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium

13. Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD

14. Laboratory of Virology, University of Paris, Cochin Hospital, Assistance Publique–Hôpitaux de Paris, Paris, France

15. Laboratory of Immunology, University of Paris, Cochin Hospital, Assistance Publique–Hôpitaux de Paris, Paris, France

16. New York Medical College, Valhalla, NY

17. Howard Hughes Medical Institute, New York, NY

Abstract

Yellow fever virus (YFV) live attenuated vaccine can, in rare cases, cause life-threatening disease, typically in patients with no previous history of severe viral illness. Autosomal recessive (AR) complete IFNAR1 deficiency was reported in one 12-yr-old patient. Here, we studied seven other previously healthy patients aged 13 to 80 yr with unexplained life-threatening YFV vaccine–associated disease. One 13-yr-old patient had AR complete IFNAR2 deficiency. Three other patients vaccinated at the ages of 47, 57, and 64 yr had high titers of circulating auto-Abs against at least 14 of the 17 individual type I IFNs. These antibodies were recently shown to underlie at least 10% of cases of life-threatening COVID-19 pneumonia. The auto-Abs were neutralizing in vitro, blocking the protective effect of IFN-α2 against YFV vaccine strains. AR IFNAR1 or IFNAR2 deficiency and neutralizing auto-Abs against type I IFNs thus accounted for more than half the cases of life-threatening YFV vaccine-associated disease studied here. Previously healthy subjects could be tested for both predispositions before anti-YFV vaccination.

Funder

Howard Hughes Medical Institute

The Rockefeller University

St. Giles Foundation

National Institutes of Health

National Center for Advancing Translational Sciences

Emergent Ventures

George Mason University

Yale Center for Mendelian Genomics

National Human Genome Research Institute

French National Research Agency

Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence